BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Nivolumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Nivolumab\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT03681561-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03681561)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Nivolumab With Ruxolitinib in Re
 lapsed or Refractory Classical Hodgkin Lymphoma\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03681561
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03743662-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03743662)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab With Radiation Therapy a
 nd Bevacizumab for Recurrent MGMT Methylated Glioblastoma\nEstimated prima
 ry completion: November 2026. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03743662
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712927-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06712927)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Trial of Relatlimab\, N
 ivolumab\, and Ipilimumab in Patients With Asymptomatic and Symptomatic Me
 lanoma Brain Metastases\nEstimated primary completion: November 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06712927
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955290-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT02955290)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: CIM
 Avax Vaccine\, Nivolumab\, and Pembrolizumab in Treating Patients With Adv
 anced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer\nEstimat
 ed primary completion: 25 November 2026. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02955290
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04735978-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04735978)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Study of RP3 Monotherapy and RP3 i
 n Combination With Nivolumab in Patients With Solid Tumours\nEstimated pri
 mary completion: 30 November 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04735978
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04900818-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04900818)
DESCRIPTION:Nivolumab\, phase 1\, Gastric Cancer.\nStudy: Study of TJ033721
  (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04900818
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03223155-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03223155)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Concurrent or Sequential Immunothe
 rapy and Radiation Therapy in Patients With Metastatic Lung Cancer\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03223155
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07176650-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07176650)
DESCRIPTION:Nivolumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Phase I
  Clinical Study To Evaluate Pharmacokinetic Profile\, Safety\, Efficacy an
 d Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced Y
 ERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatoce
 llular Carcinoma\nEstimated primary completion: December 2026. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07176650
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04283890-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04283890)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: PHP and Immunotherapy
  in Metastasized UM\nEstimated primary completion: December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04283890
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03610711-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03610711)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: REACTION (Radia
 tion Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Ni
 volumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents
  After Targeted Systemic Radiation in Patients With Advanced Esophagogastr
 ic Cancer\nEstimated primary completion: December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT03610711
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04989946-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04989946)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Androgen Deprivation\, With or W
 ithout pTVG-AR\, and With or Without T-Cell Checkpoint Blockade\, in Patie
 nts With Newly Diagnosed\, High-Risk Prostate Cancer\nEstimated primary co
 mpletion: December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT04989946
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04204837-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04204837)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab for Treatment of Squamou
 s Cell Carcinoma of the Skin\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04204837
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06151236-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06151236)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Neoadjuvant Nivolumab and Relatlim
 ab in Merkel Cell Carcinoma\nEstimated primary completion: December 2026. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06151236
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03527108-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03527108)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab Plus Ramucirumab in Patients With Recurrent\, Advanced\, Metastatic N
 SCLC\nEstimated primary completion: December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03527108
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05723055-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05723055)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Evaluating Combination of Nivoluma
 b and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Ly
 mphoma\nEstimated primary completion: December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05723055
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05476796-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05476796)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Oxaliplatin ± Nivolumab in Combin
 ation With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients Wit
 h Advanced\, Recurrent or Metastatic Gastric\, Oesophageal or Gastroesopha
 geal Junction Cancer\nEstimated primary completion: December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05476796
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263050-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05263050)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Trial of an
  Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcino
 ma and Neuroendocrine Tumors\nEstimated primary completion: December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05263050
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04912765-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04912765)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Neoanti
 gen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From 
 CRC\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04912765
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03340129-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03340129)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Anti-PD 1 Brain Collabo
 ration + Radiotherapy Extension (ABC-X Study)\nEstimated primary completio
 n: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03340129
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03803553-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03803553)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Identification and Treatment Of Mi
 crometastatic Disease in Stage III Colon Cancer\nEstimated primary complet
 ion: December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03803553
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05745233-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase na readout est. (NCT05745233)
DESCRIPTION:Nivolumab\, phase na.\nStudy: Intraperitoneal Immune Checkpoint
  Inhibitor for Malignant Ascites\nEstimated primary completion: December 2
 026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05745233
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06519682-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase na readout est. (NCT06519682)
DESCRIPTION:Nivolumab\, phase na.\nStudy: A Pilot Study Investigating Upfro
 nt Adaptive Immunotherapy Approach in Children\, Adolescent and Young Adul
 t (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliom
 as (HGG)\nEstimated primary completion: December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06519682
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04902443-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04902443)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Pomalidomide and Nivolumab in Peop
 le With Virus-Associated Malignancies With or Without HIV\nEstimated prima
 ry completion: 1 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04902443
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682728-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06682728)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Adjuvant Sa
 cituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma 
 at High-Risk Recurrence\nEstimated primary completion: 1 December 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06682728
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06237920-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06237920)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Stage II-II
 Ia Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without R
 elatlimab\nEstimated primary completion: 1 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06237920
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05647265-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05647265)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Testing the Addition of Immunother
 apy Before Surgery for Patients With Sarcomatoid Mesothelioma\nEstimated p
 rimary completion: 15 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05647265
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05678673-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Nivolumab: Phase 3 readout est. (NCT05678673)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: Study of XL
 092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-C
 lear Cell Renal Cell Carcinoma\nEstimated primary completion: 15 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05678673
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04413123-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04413123)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Cabozantini
 b In Combo With NIVO + IPI In Advanced NCCRCC\nEstimated primary completio
 n: 20 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04413123
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04606316-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04606316)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Surgical Nivolumab And Ipilimumab 
 For Recurrent GBM\nEstimated primary completion: 30 December 2026. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT04606316
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03259867-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03259867)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Combina
 tion of TATE and PD-1 Inhibitor in Liver Cancer\nEstimated primary complet
 ion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03259867
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03333616-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03333616)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab Combined With Ipilimumab
  for Patients With Advanced Rare Genitourinary Tumors\nEstimated primary c
 ompletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03333616
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03776487-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03776487)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: Nivolumab\, Ipili
 mumab and Chemoradiation in Treating Patients With Resectable Gastric Canc
 er\nEstimated primary completion: 30 December 2026. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03776487
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112549-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05112549)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Intrathecal Application of PD1 Ant
 ibody in Metastatic Solid Tumors With Leptomeningeal Disease (IT-PD1/ NOA 
 26)\nEstimated primary completion: 31 December 2026. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05112549
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05234307-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05234307)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: PBF-1
 129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small C
 ell Lung Cancer\nEstimated primary completion: 31 December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT05234307
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04835805-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04835805)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: A Study to Evaluate the
  Safety and Activity of Belvarafenib as a Single Agent and in Combination 
 With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRA
 S-mutant Advanced Melanoma.\nEstimated primary completion: 31 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04835805
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02210117-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT02210117)
DESCRIPTION:Nivolumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Nivolumab W
 ith or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patien
 ts With Metastatic Kidney Cancer That Can Be Removed by Surgery\nEstimated
  primary completion: 31 December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT02210117
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03685890-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03685890)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Evaluating the Effect
  of Nivolumab for Patients With In-transit Metastases Treated With Isolate
 d Limb Perfusion\nEstimated primary completion: 31 December 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03685890
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04180371-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04180371)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2
  Expression\nEstimated primary completion: 31 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04180371
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05597800-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05597800)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients Wi
 th HIV\, HBV\, HCV and Long Covid Syndrome\nEstimated primary completion: 
 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05597800
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05492123-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05492123)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab-ipilimumab and Chemoradi
 ation for Cervical Cancer\nEstimated primary completion: 31 December 2026.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05492123
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155317-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07155317)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Time-of-Day Specified I
 mmunotherapy for Advanced Melanoma\, The TIME Trial\nEstimated primary com
 pletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07155317
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03297606-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03297606)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Canadian Profiling and Targeted Ag
 ent Utilization Trial (CAPTUR)\nEstimated primary completion: 31 December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03297606
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05257590-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05257590)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: CVM-111
 8 in Combination With Nivolumab for Unresectable Advanced Hepatocellular C
 arcinoma\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05257590
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04953104-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04953104)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: ARID1A and/
 or KDM6A Mutation and CXCL13 Expression\nEstimated primary completion: 31 
 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04953104
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04503694-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04503694)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Neoadjuvant Regorafenib in Combina
 tion With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04503694
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02451982-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02451982)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Platform Study of Neoadjuvant and 
 Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the 
 Pancreas\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02451982
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03465592-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03465592)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Trial of Nivolumab Following Par
 tially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults W
 ith Sarcoma\nEstimated primary completion: January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03465592
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03033914-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03033914)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A(B)VD Followed by Nivolumab as 
 Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma
  (HL)\nEstimated primary completion: January 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03033914
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03520491-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03520491)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study to Test the Safety of Immu
 notherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladd
 er Cancer Patients Who Are Not Suitable for Chemotherapy\nEstimated primar
 y completion: January 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03520491
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05280457-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05280457)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients
  With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination\
 , GX-I7 and Nivolumab Combination Therapy\nEstimated primary completion: J
 anuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 280457
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03104439-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03104439)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Nivolumab and 
 Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancre
 atic Cancer\nEstimated primary completion: January 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT03104439
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731270-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06731270)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Diclo
 fenac for the Treatment of Patients With Metastatic Non-small Cell Lung Ca
 ncer on Single Agent Immunotherapy\nEstimated primary completion: 1 Januar
 y 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0673127
 0
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05136196-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05136196)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivo
 lumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and 
 Neck Cancer\, an immunoMATCH Pilot Study\nEstimated primary completion: 1 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5136196
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05122546-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05122546)
DESCRIPTION:Nivolumab\, phase 1\, Renal Cell Carcinoma.\nStudy: CBM588 in C
 ombination With Nivolumab and Cabozantinib for the Treatment of Advanced o
 r Metastatic Kidney Cancer\nEstimated primary completion: 12 January 2027.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05122546
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05584670-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05584670)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A First-in-human\, Dose Escalati
 on and Dose Expansion Study of SAR445877 in Adult Participants With Advanc
 ed Solid Tumors\nEstimated primary completion: 19 January 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05584670
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06250335-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270123
DTEND;VALUE=DATE:20270124
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06250335)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Impact of a Prebiotic F
 ood-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combin
 ation Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
 \nEstimated primary completion: 23 January 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06250335
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07334119-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07334119)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Safety\, Pharmacokinetics\, Pharma
 codynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2
 -Expressing Solid Tumors\nEstimated primary completion: 31 January 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07334119
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05176483-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05176483)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in P
 articipants With Solid Tumors\nEstimated primary completion: 31 January 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05176483
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03816358-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03816358)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Testing the Combination of Anetuma
 b Ravtansine With Either Nivolumab\, Nivolumab and Ipilimumab\, or Gemcita
 bine and Nivolumab in Advanced Pancreatic Cancer\nEstimated primary comple
 tion: 31 January 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03816358
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04079166-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04079166)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: SCIB1 and iSCIB1+ in Me
 lanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembroli
 zumab (The SCOPE Study)\nEstimated primary completion: 31 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04079166
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04472767-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04472767)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Cabozan
 tinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatoc
 ellular Carcinoma\nEstimated primary completion: 31 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04472767
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05076760-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05076760)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: MEM-2
 88 Oncolytic Virus Alone and in Combination With Standard of Care Therapy 
 in Advanced Solid Tumors\nEstimated primary completion: February 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT05076760
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04757363-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04757363)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Nivolu
 mab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative 
 Esophagogastric Cancer\nEstimated primary completion: February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04757363
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05407441-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05407441)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Tazemetostat+Nivo/Ipi in INI1-Ne
 g/SMARCA4-Def Tumors\nEstimated primary completion: 1 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT05407441
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04551430-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04551430)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Cabozantinib Combined With PD-1 an
 d CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma\nEstimated primary c
 ompletion: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04551430
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05327270-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05327270)
DESCRIPTION:Nivolumab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Non-randomized\, Open-label Study of Intralesional Nivolumab for Hig
 h Risk Oral Premalignant Lesions\nEstimated primary completion: 2 February
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05327270
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06946797-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270205
DTEND;VALUE=DATE:20270206
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06946797)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combinatio
 n With Intravenous Ipilimumab and Chemotherapy in Participants With Previo
 usly Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: 5 February 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06946797
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04047706-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04047706)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Nivolumab\, BMS-986205\, and Radia
 tion Therapy With or Without Temozolomide in Treating Patients With Newly 
 Diagnosed Glioblastoma\nEstimated primary completion: 15 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT04047706
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06319196-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06319196)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Clear Me: Interception 
 Trial to Detect and Clear Molecular Residual Disease in Patients With High
 -risk Melanoma\nEstimated primary completion: 15 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06319196
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02940301-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270215
DTEND;VALUE=DATE:20270216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02940301)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Ibrutinib and Nivolumab in Treatin
 g Patients With Relapsed or Refractory Classical Hodgkin Lymphoma\nEstimat
 ed primary completion: 15 February 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02940301
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05267626-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy of AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R
 α Binding\, in Patients With Unresectable Locally Advanced or Metastatic 
 Cancer\nEstimated primary completion: 28 February 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06047379-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Saf
 ety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Gliob
 lastoma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28
  February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06047379
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06275360-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06275360)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Repos
 itioning Immunotherapy in VetArans With Lung Cancer\nEstimated primary com
 pletion: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06275360
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226856-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07226856)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: BMS-986340 in Combination With Niv
 olumab\, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic an
 d Recurrent Pancreatic Adenocarcinoma\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 226856
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03866382-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03866382)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Testing the
  Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With 
 One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
 \nEstimated primary completion: 28 February 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03866382
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03044613-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03044613)
DESCRIPTION:Nivolumab\, phase 1\, Gastric Cancer.\nStudy: Nivolumab +/- Rel
 atlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer\nEsti
 mated primary completion: March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03044613
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05310591-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05310591)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Combination of an Anti-PD1 Antib
 ody With Tisagenlecleucel Reinfusion in Children\, Adolescents and Young A
 dults With Acute Lymphoblastic Leukemia After Loss of Persistence\nEstimat
 ed primary completion: March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05310591
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05239533-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05239533)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Study of Ni
 volumab in Combination With 177Lu-girentuximab for Kidney Cancer\nEstimate
 d primary completion: March 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05239533
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02817633-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Nivolumab: Phase 1 readout est. (NCT02817633)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Study of TSR-022 in Participants
  With Advanced Solid Tumors (AMBER)\nEstimated primary completion: 1 March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02817633
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06983210-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06983210)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Clinical Tr
 ial of AM80 in Combination With Gemcitabine\, Cisplatin\, and Nivolumab in
  Patients With Urothelial Carcinoma\nEstimated primary completion: 1 March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06983210
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03655002-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270302
DTEND;VALUE=DATE:20270303
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03655002)
DESCRIPTION:Nivolumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: IRX-2\,
  Cyclophosphamide\, and Nivolumab in Treating Patients With Recurrent or M
 etastatic and Refractory Liver Cancer\nEstimated primary completion: 2 Mar
 ch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT036550
 02
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05498792-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270304
DTEND;VALUE=DATE:20270305
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05498792)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Study of CBL0137 in Com
 bination With Ipilimumab and Nivolumab Therapy in Melanoma\nEstimated prim
 ary completion: 4 March 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05498792
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05289193-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05289193)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: CD8+ T Cell Imaging Dur
 ing Pre-surgery Immunotherapy in People With Melanoma\nEstimated primary c
 ompletion: 11 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05289193
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03873402-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270311
DTEND;VALUE=DATE:20270312
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03873402)
DESCRIPTION:Nivolumab\, phase 3\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants 
 With Advanced Kidney Cancer\nEstimated primary completion: 11 March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03873402
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03604978-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270319
DTEND;VALUE=DATE:20270320
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03604978)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Nivolumab and Multi-fraction Ste
 reotactic Radiosurgery With or Without Ipilimumab in Treating Patients Wit
 h Recurrent Grade II-III Meningioma\nEstimated primary completion: 19 Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0360497
 8
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04387084-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04387084)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Short-term Fasting Prior to PD-1/P
 D-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy\nEsti
 mated primary completion: 31 March 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT04387084
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04078295-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04078295)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Study of E7389 Liposomal Formu
 lation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor\nEstimat
 ed primary completion: 31 March 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04078295
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04310007-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04310007)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Testi
 ng the Addition of the Pill Chemotherapy\, Cabozantinib\, to the Standard 
 Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small C
 ell Lung Cancer\nEstimated primary completion: 31 March 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04310007
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06064097-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06064097)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study Using Nivolumab\, in Combi
 nation With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)\nEs
 timated primary completion: 31 March 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06064097
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03391869-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03391869)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab and Ipilimumab With or Without Local Consolidation Therapy in Treatin
 g Patients With Stage IV Non-Small Cell Lung Cancer\nEstimated primary com
 pletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT03391869
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04444921-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04444921)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: EA2176: Phase 3 Clinical Trial of 
 Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patient
 s\nEstimated primary completion: 31 March 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT04444921
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07422779-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Nivolumab: Phase na readout est. (NCT07422779)
DESCRIPTION:Nivolumab\, phase na\, Melanoma.\nStudy: Immunotherapy Efficacy
  and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia\nE
 stimated primary completion: 31 March 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07422779
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04741997-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04741997)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Adjuvant Therapy Based 
 on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melano
 ma\nEstimated primary completion: April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04741997
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04730544-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04730544)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Two Combinatio
 n Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and
  / or MSI mCRC.\nEstimated primary completion: April 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT04730544
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04848116-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04848116)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Neoadjuvant Targeting of Myeloid Cell Populations in Combination Wit
 h Nivolumab in Head & Neck Ca\nEstimated primary completion: April 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT04848116
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03122522-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03122522)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: A Study to Evaluate Ada
 ptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy\nEstima
 ted primary completion: April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT03122522
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07221734-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07221734)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Study to Compare Pharma
 cokinetics\, Efficacy\, Safety\, and Immunogenicity of MB11 Versus EU-/US-
 Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or M
 etastatic] Melanoma\nEstimated primary completion: April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07221734
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05254184-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05254184)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: KRAS-
 Targeted Vaccine With Chemoimmunotherapy\, Nivolumab and Ipilimumab for Pa
 tients With NSCLC\nEstimated primary completion: 1 April 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05254184
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05919264-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05919264)
DESCRIPTION:Nivolumab\, phase 1/2\, Colorectal Cancer.\nStudy: FOG-001 in L
 ocally Advanced or Metastatic Solid Tumors\nEstimated primary completion: 
 1 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5919264
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03097939-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270405
DTEND;VALUE=DATE:20270406
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03097939)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Phase 2 Trial of Ipilimumab and Ni
 volumab in Nasopharyngeal Carcinoma\nEstimated primary completion: 5 April
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03097939
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187869-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270407
DTEND;VALUE=DATE:20270408
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07187869)
DESCRIPTION:Nivolumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Modulation 
 of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bo
 ne Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study\nEst
 imated primary completion: 7 April 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07187869
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03690986-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03690986)
DESCRIPTION:Nivolumab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: VX15/2503 in Combination With Ipilimumab or Nivolumab in Patients Wi
 th Head and Neck Cancer\nEstimated primary completion: 9 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03690986
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02393625-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270409
DTEND;VALUE=DATE:20270410
SUMMARY:Nivolumab: Phase 1 readout est. (NCT02393625)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Study
  of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Pati
 ents With ALK-positive Non-small Cell Lung Cancer\nEstimated primary compl
 etion: 9 April 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT02393625
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03707808-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270423
DTEND;VALUE=DATE:20270424
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03707808)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Intratumoral Injection of Autolo
 gous CD1c (BDCA-1)+ myDC\, AS01B\, and Ipilimumab Plus Systemic Nivolumab\
 nEstimated primary completion: 23 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT03707808
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05802056-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05802056)
DESCRIPTION:Nivolumab\, phase 1\, Gastric Cancer.\nStudy: Aldesleukin With 
 Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With P
 eritoneal Metastasis\nEstimated primary completion: 24 April 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05802056
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05162976-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05162976)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: CC-486 and Nivolumab for the Treat
 ment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed\nEstimated
  primary completion: 27 April 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05162976
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364917-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06364917)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: DISCE
 RN: Dual Versus Single ICB in PDL-1 Negative NSCLC\nEstimated primary comp
 letion: 27 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06364917
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03589339-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03589339)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: NBTXR
 3 Activated by Radiotherapy for Patients With Advanced Cancers Treated Wit
 h An Anti-PD-1 Therapy\nEstimated primary completion: 30 April 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT03589339
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03449108-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03449108)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: LN-145 or LN-145-S1 in Treating Pa
 tients With Relapsed or Refractory Ovarian Cancer\, Triple Negative Breast
  Cancer (TNBC)\, Anaplastic Thyroid Cancer\, Osteosarcoma\, or Other Bone 
 and Soft Tissue Sarcomas\nEstimated primary completion: 30 April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT03449108
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05384496-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05384496)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Axitinib and Nivolumab 
 for the Treatment of Mucosal Melanoma\nEstimated primary completion: May 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05384496
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04322955-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04322955)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: CYTO Reduct
 ive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibi
 tion\nEstimated primary completion: May 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04322955
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05845450-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05845450)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Pre-operative 
 Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (
 UNICORN)\nEstimated primary completion: May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT05845450
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04506554-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04506554)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study of Risk Enabled Therapy Af
 ter Neoadjuvant Immunochemotherapy for Bladder Cancer\nEstimated primary c
 ompletion: May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT04506554
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06265285-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06265285)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Compa
 rison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab
  Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls 
 (CCBW) Program\nEstimated primary completion: 1 May 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06265285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919717-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07919717)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: NIVO+IP
 I Neoadjuvant Therapy for Recurrent Resectable HCC\nEstimated primary comp
 letion: 12 May 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07919717
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561087-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06561087)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Phase II Randomized\, Placebo- Con
 trolled Study of Intralesional Nivolumab for High-risk Oral Premalignant L
 esions\nEstimated primary completion: 30 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06561087
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04957615-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04957615)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab for the Treatment of Met
 astatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expre
 ssion\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT04957615
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02595944-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT02595944)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab After Surgery and Chemotherapy in Treating Patients With Stage IB-III
 A Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)\nEstimated pri
 mary completion: 31 May 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT02595944
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05733689-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05733689)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Response Adapted Neoadjuvant Thera
 py in Gastroesophageal Cancers (RANT-GC Trial)\nEstimated primary completi
 on: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 05733689
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05681780-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05681780)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Clini
 cal Trial of CD40L-Augmented TIL for Patients With EGFR\, ALK\, ROS1 or HE
 R2-Driven NSCLC\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05681780
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03918252-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03918252)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Neoadjuvant Immune Checkpoint Bloc
 kade in Resectable Malignant Pleural Mesothelioma\nEstimated primary compl
 etion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03918252
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06015724-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06015724)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pa
 ncreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer\n
 Estimated primary completion: June 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06015724
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03546686-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03546686)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Peri-Operative Immune Checkpoint I
 nhibition and Cryoablation in Women With Triple-negative Breast Cancer\nEs
 timated primary completion: June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT03546686
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06097975-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06097975)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Clinical Trial on Combined (Neo-
 )Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and N
 ivolumab in Recurrent Glioblastoma\nEstimated primary completion: 1 June 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06097975
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04117087-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04117087)
DESCRIPTION:Nivolumab\, phase 1\, Colorectal Cancer.\nStudy: Pooled Mutant 
 KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab 
 for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and 
 Pancreatic Cancer\nEstimated primary completion: 1 June 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04117087
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03025256-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03025256)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Intra
 venous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal 
 Disease\nEstimated primary completion: 1 June 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT03025256
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05912244-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05912244)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: A Study of IO102/IO103\
 , Nivolumab\, and Relatlimab in People With Melanoma\nEstimated primary co
 mpletion: 9 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05912244
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05272384-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270628
DTEND;VALUE=DATE:20270629
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05272384)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Testing the Combination of Nivolum
 ab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma\nEstimated prima
 ry completion: 28 June 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05272384
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532344-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06532344)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: An Open-label\, Uncontrolled Study
  of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy\
 , the Standard of Care\, as First-line Treatment in Patients With Metastat
 ic Pancreatic Cancer\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06532344
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04495296-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04495296)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Trial to Evaluate Safety\, Tol
 erability\, Pharmacokinetics and Preliminary Efficacy of TST001 in Advance
 d or Metastatic Solid Tumors\nEstimated primary completion: 30 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04495296
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04396821-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04396821)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: A Trial to Eval
 uate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tum
 ors\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04396821
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01896999-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT01896999)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Brentuximab Vedotin and Nivoluma
 b With or Without Ipilimumab in Treating Patients With Relapsed or Refract
 ory Hodgkin Lymphoma\nEstimated primary completion: 30 June 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT01896999
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04831320-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04831320)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or M
 etastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 
 or PD-L1 Inhibitor\nEstimated primary completion: 30 June 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04831320
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05034536-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05034536)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: PD-1 Antibody Therapy +
  Infliximab for Metastatic Melanoma\nEstimated primary completion: 30 June
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05034536
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03505320-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03505320)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: A Study of Zolbet
 uximab (IMAB362) in Adults With Gastric Cancer\nEstimated primary completi
 on: 30 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT03505320
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511013-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04511013)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: A Study to Compare the 
 Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab 
 + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases\nEstimated 
 primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04511013
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04751370-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04751370)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Testing Nivolumab and Ipilimumab W
 ith Short-Course Radiation in Locally Advanced Rectal Cancer\nEstimated pr
 imary completion: 30 June 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT04751370
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04145115-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04145115)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study Testing the Effect of Immu
 notherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma Wit
 h Elevated Mutational Burden\nEstimated primary completion: 30 June 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04145115
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04759586-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04759586)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Nivolumab in Combination With Chem
 o-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B
 -Cell Lymphoma\nEstimated primary completion: 30 June 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04759586
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06638931-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06638931)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Agnostic Th
 erapy in Rare Solid Tumors\nEstimated primary completion: July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06638931
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05732389-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05732389)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Immunotherapy in Patients With Ear
 ly dMMR Rectal Cancer\nEstimated primary completion: July 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05732389
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03521830-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03521830)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab Alone or Plus Relatlimab
  or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastat
 ic Basal Cell Carcinoma\nEstimated primary completion: July 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03521830
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07084610-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07084610)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Metab
 olic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Sm
 all Cell Lung Cancer\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07084610
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05111574-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05111574)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Using Nivolumab Alone o
 r With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery\nEsti
 mated primary completion: 15 July 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05111574
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347212-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270716
DTEND;VALUE=DATE:20270717
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05347212)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Phase II Trial of Immunotherapy in
  Patients With Carcinomas Arising From the Renal Medulla\nEstimated primar
 y completion: 16 July 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT05347212
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02496208-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Nivolumab: Phase 1 readout est. (NCT02496208)
DESCRIPTION:Nivolumab\, phase 1\, Urothelial Carcinoma.\nStudy: Cabozantini
 b S-malate and Nivolumab With or Without Ipilimumab in Treating Patients W
 ith Metastatic Genitourinary Tumors\nEstimated primary completion: 30 July
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT02496208
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07149090-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07149090)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: Lenvatinib in C
 ombination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer P
 atients With Malignant Ascites\nEstimated primary completion: 30 July 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07149090
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02845323-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02845323)
DESCRIPTION:Nivolumab\, phase 2\, Urothelial Carcinoma.\nStudy: Neoadjuvant
  Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemothera
 py-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Blad
 der\nEstimated primary completion: 31 July 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02845323
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377111-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06377111)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: A Study to Test the Ben
 efit of Vitamin B5 in Patients With Melanoma\nEstimated primary completion
 : August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06377111
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05901285-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05901285)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Phase 1 Study of Intratumoral Admi
 nistration of VAX014 With Expansion in Combination With a Checkpoint Inhib
 itor in Subjects With Advanced Solid Tumors\nEstimated primary completion:
  August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5901285
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03635892-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03635892)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Study of 
 Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell
  Renal Cell Carcinoma\nEstimated primary completion: August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT03635892
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663775-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05663775)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Prophylactic Mesalamine
  to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Niv
 o)\nEstimated primary completion: August 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05663775
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03576417-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03576417)
DESCRIPTION:Nivolumab\, phase 3\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Tre
 atment of Cancers of the Head and Neck\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT035764
 17
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07075120-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07075120)
DESCRIPTION:Nivolumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Ipilimu
 mab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer\nEst
 imated primary completion: 1 August 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07075120
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03502733-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03502733)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Testing the Combination of Copanli
 sib\, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lympho
 ma\nEstimated primary completion: 1 August 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03502733
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04609046-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04609046)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Testing the Addition of Lenalidomi
 de and Nivolumab to the Usual Treatment for Primary CNS Lymphoma\nEstimate
 d primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04609046
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05964101-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05964101)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab Combined With Chemothera
 py in the Treatment of Primary Tracheal Squamous Cell Carcinoma\nEstimated
  primary completion: 1 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05964101
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05896839-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270802
DTEND;VALUE=DATE:20270803
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05896839)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Immunotherapy in Comb
 ination With Prednisone and Sirolimus for Kidney Transplant Recipients Wit
 h Unresectable or Metastatic Skin Cancer\nEstimated primary completion: 2 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 896839
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04745949-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270803
DTEND;VALUE=DATE:20270804
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04745949)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: PACIFIC: Primary Mediastinal Large
  B-cell Lymphoma Treated With Antibody Therapy\, Checkpoint Inhibitor in F
 rontline With ImmunoChemotherapy\nEstimated primary completion: 3 August 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04745949
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476326-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270816
DTEND;VALUE=DATE:20270817
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07476326)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Pharmacokinetics\, Safe
 ty\, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Mo
 notherapy in Participants With Melanoma\nEstimated primary completion: 16 
 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 476326
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06646276-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270817
DTEND;VALUE=DATE:20270818
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06646276)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: A Study to Compare the Efficacy an
 d Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in C
 ombination With Carboplatin Plus Etoposide to That of Atezolizumab With Ca
 rboplatin Plus Etoposide as First-Line Therapy in Participants With Extens
 ive-Stage Small Cell Lung Cancer (TIGOS).\nEstimated primary completion: 1
 7 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06646276
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05672173-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270824
DTEND;VALUE=DATE:20270825
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05672173)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Lisocabtagene Maraleucel\, Nivolum
 ab and Ibrutinib for the Treatment of Richter's Transformation\nEstimated 
 primary completion: 24 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05672173
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: The Drug Rediscovery Protocol (DRU
 P Trial)\nEstimated primary completion: September 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152678-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07152678)
DESCRIPTION:Nivolumab\, phase 2\, Esophageal Squamous Cell Carcinoma.\nStud
 y: Brachytherapy With Radiotherapy and Immunotherapy: Guided HDR Trial in 
 Esophageal Squamous Cell Carcinoma\nEstimated primary completion: Septembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0715267
 8
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06253611-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06253611)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: First-line EXL01 
 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT06253611
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07213557-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07213557)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Simvastatin Efficacy in ARID1A Mut
 ated Advanced gastroESophageal Carcinoma Treated With Immunotherapy\nEstim
 ated primary completion: September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07213557
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03282344-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03282344)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study of NKTR-214 in Combination
  With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcom
 a\nEstimated primary completion: September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT03282344
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04106414-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04106414)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study of BMS-986205 and Nivolumab 
 in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded
  to Treatment\nEstimated primary completion: September 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04106414
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04309409-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04309409)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Adjuvant Nivolumab Trea
 tment in Stage II (IIA\, IIB\, IIC) High-risk Melanoma\nEstimated primary 
 completion: September 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT04309409
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02978625-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02978625)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Talimogene Laherparepvec and Nivol
 umab in Treating Patients With Refractory Lymphomas or Advanced or Refract
 ory Non-melanoma Skin Cancers\nEstimated primary completion: 1 September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT02978625
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06532331-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06532331)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A PhaseⅠStudy of ONO-7475 in Com
 bination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP)\, the Sta
 ndard of Care\, and ONO-7475 in Combination With GnP in Patients With Panc
 reatic Cancer\nEstimated primary completion: 30 September 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06532331
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04697576-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04697576)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Intralesional Influenza
  Vaccine for the Treatment of Stage I-IV Melanoma\nEstimated primary compl
 etion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT04697576
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04884282-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04884282)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Effic
 acy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Thera
 py in Metastatic Non-small-cell Lung Cancer Progressing After First-line C
 hemo-immunotherapy (Combi-TED)\nEstimated primary completion: 30 September
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04884282
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02530463-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02530463)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab and/or Ipilimumab With o
 r Without Azacitidine in Treating Patients With Myelodysplastic Syndrome\n
 Estimated primary completion: 30 September 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT02530463
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03607890-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03607890)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study of Nivolumab and Relatlimab 
 in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 I
 nhibitor\nEstimated primary completion: October 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03607890
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05361720-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05361720)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Genetic Tes
 ting to Select Therapy for the Treatment of Advanced or Metastatic Kidney 
 Cancer\, OPTIC RCC Study\nEstimated primary completion: 1 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT05361720
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174453-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07174453)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Trial to Evaluate irAEs With Diffe
 rent Standard of Care Dosing Strategies of Standard of Care Immunotherapie
 s\nEstimated primary completion: 1 October 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07174453
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04561206-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271002
DTEND;VALUE=DATE:20271003
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04561206)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Brentuximab Vedotin and Nivolumab 
 for the Treatment of Patients With Relapsed/Refractory Classical Hodgkin L
 ymphoma\nEstimated primary completion: 2 October 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04561206
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03884998-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271007
DTEND;VALUE=DATE:20271008
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03884998)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Copanlisib and Nivolumab in Treati
 ng Patients With Richter's Transformation or Transformed Indolent Non-Hodg
 kin Lymphoma\nEstimated primary completion: 7 October 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03884998
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06544655-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271014
DTEND;VALUE=DATE:20271015
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06544655)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Study of BMS-986484 Alone and Co
 mbination Therapy in Participants With Advanced Solid Tumors\nEstimated pr
 imary completion: 14 October 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT06544655
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06764771-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06764771)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Study of BMS-986488 as Monothera
 py and Combination Therapy in Participants With Advanced Malignant Tumors\
 nEstimated primary completion: 15 October 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06764771
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05012254-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271015
DTEND;VALUE=DATE:20271016
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05012254)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Nivol
 umab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Canc
 er With Brain Metastases\nEstimated primary completion: 15 October 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05012254
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06112314-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271016
DTEND;VALUE=DATE:20271017
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06112314)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: IMC-F106C Regimen Versu
 s Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-
 301)\nEstimated primary completion: 16 October 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06112314
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05663710-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05663710)
DESCRIPTION:Nivolumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 1b/
 2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab 
 in Treatment naïve Patients With Advanced Clear Cell RCC\nEstimated prima
 ry completion: 30 October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05663710
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07376707-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07376707)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Pha
 se 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Su
 bjects With Locally Advanced/Metastatic Solid Tumors\nEstimated primary co
 mpletion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07376707
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06547385-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06547385)
DESCRIPTION:Nivolumab\, phase 1\, Colorectal Cancer.\nStudy: Study of ONO-4
 578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer\nEstimated prim
 ary completion: 31 October 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06547385
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03307616-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03307616)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab With and Without Ipilimu
 mab and Radiation Therapy in Treating Patients With Recurrent or Resectabl
 e Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Bef
 ore Surgery\nEstimated primary completion: 31 October 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03307616
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06203600-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT06203600)
DESCRIPTION:Nivolumab\, phase 2/3\, Gastric Cancer.\nStudy: Adding Nivoluma
 b to Usual Treatment for People With Advanced Stomach or Esophageal Cancer
 \, PARAMUNE Trial\nEstimated primary completion: 31 October 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06203600
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04162015-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04162015)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Study of Nivolumab and Chemother
 apy Followed by Surgery for Mesothelioma\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 162015
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06132945-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06132945)
DESCRIPTION:Nivolumab\, phase 1\, Renal Cell Carcinoma.\nStudy: A Study of 
 Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Ce
 ll Carcinoma That Has Spread to the Brain\nEstimated primary completion: N
 ovember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6132945
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06901817-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06901817)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy of the Safety and Efficacy of Pemetrexed Combined with Nivolumab Via In
 traventricular Injection for the Treatment of Refractory Non-squamous Non-
 small Cell Lung Cancer with Leptomeningeal Metastases\nEstimated primary c
 ompletion: November 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06901817
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03406247-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03406247)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamo
 us Cell Carcinoma\nEstimated primary completion: November 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03406247
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05098210-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05098210)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Perso
 nalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Mel
 anoma\, Hormone Receptor Positive HER2 Negative Metastatic Refractory Brea
 st Cancer or Stage III-IV Non-Small Cell Lung Cancer\nEstimated primary co
 mpletion: 1 November 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05098210
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07401875-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07401875)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Phase 1b Study of HC-7366\, an A
 gonist of ISR With Immunotherapy in Kidney Cancer (SHARK)\nEstimated prima
 ry completion: 30 November 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07401875
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03838159-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03838159)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: NADIM
  II: Neo-Adjuvant Immunotherapy\nEstimated primary completion: 30 November
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03838159
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039073-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05039073)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Brentuximab Vedotin and Nivolumab 
 for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previous
 ly Treated With Brentuximab Vedotin or Checkpoint Inhibitors\nEstimated pr
 imary completion: 30 November 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05039073
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07209059-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07209059)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: PET-Adapted First-Line Therapy Wit
 h Nivolumab for Advanced Hodgkin Lymphoma\nEstimated primary completion: D
 ecember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7209059
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04150640-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04150640)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Oxaliplatin and Liposomal Irinotec
 an (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and
  Gastric Adenocarcinoma\nEstimated primary completion: December 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT04150640
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230613-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07230613)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neo-adjuvant Immunother
 apy in Patients With Localized Melanoma\nEstimated primary completion: Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT072
 30613
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07364474-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase na readout est. (NCT07364474)
DESCRIPTION:Nivolumab\, phase na\, Melanoma.\nStudy: Immune Response to Per
 cutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic 
 to the Liver\nEstimated primary completion: December 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07364474
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653503-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07653503)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Neoadjuvant Lymph Node Targeted Im
 munotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)\nEstimated p
 rimary completion: 1 December 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07653503
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Nivolumab With Trametin
 ib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients Wi
 th BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstimate
 d primary completion: 8 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04017650-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04017650)
DESCRIPTION:Nivolumab\, phase 1/2\, Colorectal Cancer.\nStudy: Encorafenib\
 , Cetuximab\, and Nivolumab in Treating Patients With Microsatellite Stabl
 e\, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer\nEstima
 ted primary completion: 30 December 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT04017650
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04061980-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04061980)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Encorafenib and Binimetinib With o
 r Without Nivolumab in Treating Patients With Metastatic Radioiodine Refra
 ctory BRAF V600 Mutant Thyroid Cancer\nEstimated primary completion: 30 De
 cember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 061980
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06540261-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06540261)
DESCRIPTION:Nivolumab\, phase 1\, Colorectal Cancer.\nStudy: The Study of O
 NO-7913\, ONO-4538 and the Standard of Care as First-line Treatment in Pat
 ients Colorectal Cancer\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06540261
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04930783-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04930783)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: NeoVax + CDX-301 and Ni
 volumab or Pembrolizumab in Melanoma\nEstimated primary completion: 31 Dec
 ember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 30783
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04013542-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04013542)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: Ipili
 mumab and Nivolumab in Combination With Radiation Therapy in Treating Pati
 ents With Stage 2-3 Non-small Lung Cancer\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivo
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04013542
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05655312-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05655312)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: MC1R-targeted Alpha-p
 article Monotherapy and Combination Therapy Trial With Nivolumab in Adults
  With Advanced Melanoma\nEstimated primary completion: 31 December 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05655312
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04165330-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04165330)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Eva
 luation of AL3818 in Combination With Nivolumab in Solid Tumors\nEstimated
  primary completion: 31 December 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04165330
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06362369-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06362369)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed 
 by Nivolumab Monotherapy\nEstimated primary completion: 31 December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06362369
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02696993-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT02696993)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Niv
 olumab and Radiation Therapy With or Without Ipilimumab in Treating Patien
 ts With Brain Metastases From Non-small Cell Lung Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT02696993
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04566380-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04566380)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: ONO-4538 Phase II Rollover Study (
 ONO-4538-98)\nEstimated primary completion: 31 December 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04566380
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06692491-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06692491)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study of Precision Treatment for R
 are Tumours in China Guided by PDO and NGS\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06692491
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: TAPUR: Testing the Use of Food and
  Drug Administration (FDA) Approved Drugs That Target a Specific Abnormali
 ty in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primary
  completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04729322-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04729322)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Fecal Microbio
 ta Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or N
 ivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 N
 on-responders\nEstimated primary completion: 31 December 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT04729322
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05048212-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05048212)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase II 
 Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untre
 ated Renal Cell Carcinoma Brain Metastases\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05048212
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06863311-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06863311)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Trial of Za
 nzalintinib (XL092) in Combination With Immunotherapy in Patients Who Prog
 ress on Adjuvant Therapy in Clear Cell RCC\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06863311
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04875611-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04875611)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab in Nasopharyngeal Cancer
  With Progression During or After Platinum-based Treatment\nEstimated prim
 ary completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04875611
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direct
 ed by Genetic Testing in Treating Patients With Advanced Refractory Solid 
 Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03233711-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03233711)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Nivolumab After Combined Modality 
 Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT03233711
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564570-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Nivolumab: Phase na readout est. (NCT07564570)
DESCRIPTION:Nivolumab\, phase na\, Melanoma.\nStudy: Physical Activity Dire
 ctly Before Immunotherapy (Nivolumab and Ipilimumab) in Melanoma\nEstimate
 d primary completion: 31 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07564570
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06984146-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06984146)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivo40-AVD for Advanced Classic Ho
 dgkin Lymphoma\nEstimated primary completion: January 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06984146
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05779423-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05779423)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Cryoablation+Ipilimumab
 +Nivolumab in Melanoma\nEstimated primary completion: 1 January 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05779423
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05788081-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05788081)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Treatment Of Newly-diagnosed Folli
 cular Lymphoma With CELMoD Golcadomide\, Rituximab +/- Nivolumab.\nEstimat
 ed primary completion: 1 January 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT05788081
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06054555-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280125
DTEND;VALUE=DATE:20280126
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06054555)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: A Study to Evaluate ABP
  206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or M
 etastatic Melanoma\nEstimated primary completion: 25 January 2028. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06054555
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06163820-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280130
DTEND;VALUE=DATE:20280131
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06163820)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Bevacizumab and ICIs 
 + hSRT in Symptomatic Melanoma Brain Metastases\nEstimated primary complet
 ion: 30 January 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06163820
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05504252-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05504252)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: METIMMOX-2: Me
 tastatic pMMR/MSS Colorectal Cancer - Shaping Anti-Tumor Immunity by Oxali
 platin\nEstimated primary completion: 31 January 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05504252
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948448-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280215
DTEND;VALUE=DATE:20280216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06948448)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: A Study to Eva
 luate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®
 \, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in
  Participants With Non-MSI-H/dMMR\, PD-L1 Positive Advanced Colorectal Can
 cer\nEstimated primary completion: 15 February 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06948448
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862530-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280227
DTEND;VALUE=DATE:20280228
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07862530)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant RP2 + Nivol
 umab in Patients With Melanoma\nEstimated primary completion: 27 February 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07862530
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07404332-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07404332)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: 5-Azacitidine Plus PD-1/PD-L1 Inhi
 bitor With PD-1/PD-L1 Refractory Tumors\nEstimated primary completion: 28 
 February 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07404332
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380545-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04380545)
DESCRIPTION:Nivolumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Nivol
 umab\, Fluorouracil\, and Interferon Alpha 2B for the Treatment of Unresec
 table Fibrolamellar Cancer\nEstimated primary completion: 28 February 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04380545
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06800339-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06800339)
DESCRIPTION:Nivolumab\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy Evaluating Neoadjuvant Chemoimmunotherapy With Immunosensitizing Radiat
 ion for Borderline Resectable Non-Small Cell Lung Cancer\nEstimated primar
 y completion: March 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06800339
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03155061-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03155061)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Study of ONO-4578 With and Without
  ONO-4538 in Subjects Advanced or Metastatic Solid Tumors\nEstimated prima
 ry completion: March 2028. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03155061
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06896110-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06896110)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Intrathecal Azacitidine and Nivolu
 mab in Patients With Recurrent High-grade Glioma\nEstimated primary comple
 tion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06896110
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999980-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06999980)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neo IRENIE (NEOadjuvant
  Ipilimumab\, RElatlimab\, NIvolumab Evaluation)\nEstimated primary comple
 tion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/niv
 olumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06999980
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05684276-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280301
DTEND;VALUE=DATE:20280302
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05684276)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: DUMAS
 : Neo-Adjuvant Immunotherapy for Pancoast Tumors\nEstimated primary comple
 tion: 1 March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/n
 ivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05684276
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05428007-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280317
DTEND;VALUE=DATE:20280318
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05428007)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Interleukin-6 Receptor 
 Inhibitor Sarilumab in Combination With Ipilimumab\, Nivolumab and Relatli
 mab in Patients With Unresectable Stage III or Stage IV Melanoma\nEstimate
 d primary completion: 17 March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05428007
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03816345-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03816345)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Testing an Immunotherapy Anti-canc
 er Drug\, Nivolumab\, for Advanced Cancers in Patients With Autoimmune Dis
 orders\, AIM-NIVO\nEstimated primary completion: 30 March 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03816345
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07542262-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280330
DTEND;VALUE=DATE:20280331
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07542262)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Low-dose Immun
 otherapy in Metastatic and Locally Advanced Colorectal and Gastric MSI/dMM
 R Cancers\nEstimated primary completion: 30 March 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07542262
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05423262-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05423262)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: A Study of TRK-950 in
  Patients With Advanced Solid Tumors\nEstimated primary completion: 31 Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT054232
 62
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07319195-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07319195)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Window Study of Intratumoral Mitaz
 alimab in Breast Cancer (WINIT-BC)\nEstimated primary completion: April 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07319195
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934057-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nivolumab: Phase 4 readout est. (NCT06934057)
DESCRIPTION:Nivolumab\, phase 4\, Renal Cell Carcinoma.\nStudy: Cabozantini
 b and Nivolumab Among Older Patients With Renal Cell Carcinoma\nEstimated 
 primary completion: April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06934057
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100704-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280414
DTEND;VALUE=DATE:20280415
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07100704)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Recurrent/Metastatic Olfactory Neu
 roblastoma: Evaluating the Efficacy and Safety of Nivolumab\nEstimated pri
 mary completion: 14 April 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07100704
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04725474-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04725474)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: First-in-Human Study of the GDF-
 15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Ca
 ncer (GDFATHER)\nEstimated primary completion: 30 April 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04725474
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06624475-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06624475)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Neoadjuvant Nivolumab + Relatlimab
  (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma
 \nEstimated primary completion: May 2028. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06624475
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07017816-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07017816)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Phase 0/1 Study of cDNA for TP53
 \, Checkpoint Inhibition and Radiation in Children With Recurrent\, Progre
 ssive or Refractory CNS Malignancies.\nEstimated primary completion: 1 May
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07017816
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03767348-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03767348)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Study
  of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)\nEstima
 ted primary completion: June 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03767348
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03080974-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03080974)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Immunotherapy and Irreversible Ele
 ctroporation in the Treatment of Advanced Pancreatic Adenocarcinoma\nEstim
 ated primary completion: 1 June 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03080974
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07494435-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07494435)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Phase 2 Study of WGI-0301 Plus Niv
 olumab in Patients With HCC and RCC\nEstimated primary completion: 1 June 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07494435
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794229-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06794229)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Neoadjuvant
  Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Ino
 perable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Met
 astasis\nEstimated primary completion: 6 June 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06794229
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04995003-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04995003)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: HER2 Chimeric Antigen Receptor (CA
 R) T Cells in Combination With Checkpoint Blockade in Patients With Advanc
 ed Sarcoma\nEstimated primary completion: 30 June 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT04995003
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04323046-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04323046)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Immunotherapy Before and After Sur
 gery for Treatment of Recurrent or Progressive High Grade Glioma in Childr
 en and Young Adults\nEstimated primary completion: 30 June 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04323046
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317000-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05317000)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: 5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC\nE
 stimated primary completion: 30 June 2028. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05317000
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03110978-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03110978)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Stere
 otactic Body Radiation Therapy With or Without Nivolumab in Treating Patie
 nts With Stage I-IIA or Recurrent Non-small Cell Lung Cancer\nEstimated pr
 imary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03110978
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04546399-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04546399)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study to Compare Blinatumomab Al
 one to Blinatumomab With Nivolumab in Patients Diagnosed With First Relaps
 e B-Cell Acute Lymphoblastic Leukemia (B-ALL)\nEstimated primary completio
 n: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivo
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04546399
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06031233-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nivolumab: Phase 4 readout est. (NCT06031233)
DESCRIPTION:Nivolumab\, phase 4.\nStudy: Evaluating the Safety of Shortened
  Infusion Times for dIfferent Oncological Immunotherapie\nEstimated primar
 y completion: July 2028. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06031233
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06204614-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06204614)
DESCRIPTION:Nivolumab\, phase 1\, Urothelial Carcinoma.\nStudy: Drug Screen
 ing Using IMD in Bladder Cancer\nEstimated primary completion: 1 July 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06204614
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05909618-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05909618)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Crizanlizumab Alone or 
 in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Met
 astases\nEstimated primary completion: 30 July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05909618
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187182-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05187182)
DESCRIPTION:Nivolumab\, phase 1\, Gastric Cancer.\nStudy: CA-4948 in Combin
 ation With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectabl
 e Gastric and Esophageal Cancer\nEstimated primary completion: 31 July 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05187182
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07631325-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07631325)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Axelopran and Nivolum
 ab in PD-1-Refractory Metastatic Melanoma\nEstimated primary completion: 3
 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 631325
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05704647-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05704647)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Phase II Study of Nivol
 umab in Combination With Relatlimab in Patients With Active Melanoma Brain
  Metastases\nEstimated primary completion: 31 July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05704647
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07420439-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07420439)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Treat
 ment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstit
 ial Lung Disease\nEstimated primary completion: 15 August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07420439
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07492680-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280815
DTEND;VALUE=DATE:20280816
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07492680)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Study of Navlimetostat (BMS-9865
 04) Monotherapy and in Combination With Other Agents in Participants With 
 Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (Mou
 ntainTAP-5)\nEstimated primary completion: 15 August 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07492680
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07128680-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280825
DTEND;VALUE=DATE:20280826
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07128680)
DESCRIPTION:Nivolumab\, phase 1\, Renal Cell Carcinoma.\nStudy: Immunothera
 py (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Produ
 ct (EXL01) for the Treatment of Metastatic Renal Cell Cancer\nEstimated pr
 imary completion: 25 August 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07128680
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07514767-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07514767)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Evaluation of the Efficacy and Saf
 ety of Nivolumab Neoadjuvant Treatment of Patients With Locally Advanced O
 ral Squamous Cell Carcinoma\nEstimated primary completion: September 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07514767
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902258-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280902
DTEND;VALUE=DATE:20280903
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07902258)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: An Exploratory Study of Single-Dos
 e Neoadjuvant Nivolumab Without Surgical Delay in Patients With Resectable
  HCC\nEstimated primary completion: 2 September 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07902258
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07028125-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Nivolumab: Phase 4 readout est. (NCT07028125)
DESCRIPTION:Nivolumab\, phase 4\, Renal Cell Carcinoma.\nStudy: Digital Mon
 itoring of Self-reported Symptoms by Patients Treated With Cabozantinib Pl
 us Nivolumab for Advanced Clear-cell Renal Carcinoma\nEstimated primary co
 mpletion: October 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07028125
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06284564-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06284564)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Phase II 
 Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evol
 ocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOO
 ST-RCC)\nEstimated primary completion: 1 October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06284564
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07233668-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Nivolumab: Phase na readout est. (NCT07233668)
DESCRIPTION:Nivolumab\, phase na\, Renal Cell Carcinoma.\nStudy: Immediate 
 Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRC
 C\nEstimated primary completion: 1 October 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07233668
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06534190-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06534190)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: CD8 PET Imaging in Metastatic Soli
 d Tumours\nEstimated primary completion: November 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06534190
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06295159-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06295159)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Neoadjuvant and Adjuvan
 t Anti-PD1 or Combinations for Locoregionally Advanced Melanoma\nEstimated
  primary completion: November 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06295159
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05501054-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05501054)
DESCRIPTION:Nivolumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Phase 1b/
 2 Trial of Ipilimumab\, Nivolumab\, and Ciforadenant (Adenosine A2a Recept
 or Antagonist) in First-line Advanced Renal Cell Carcinoma.\nEstimated pri
 mary completion: 1 November 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05501054
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06053658-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281101
DTEND;VALUE=DATE:20281102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06053658)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: Phase 2 Stu
 dy of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal
  Cell Carcinoma\nEstimated primary completion: 1 November 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06053658
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04605146-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281105
DTEND;VALUE=DATE:20281106
SUMMARY:Nivolumab: Phase na readout est. (NCT04605146)
DESCRIPTION:Nivolumab\, phase na\, Melanoma.\nStudy: Impact of Telemonitori
 ng for the Management of Side Effects in Patients with Melanoma\, Lung or 
 Renal Cancer\, Treated with Immunotherapy Combination of Nivolumab and Ipi
 limumab or Adjuvant Nivolumab Monotherapy\nEstimated primary completion: 5
  November 2028. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04605146
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05677490-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281108
DTEND;VALUE=DATE:20281109
SUMMARY:Nivolumab: Phase 3 readout est. (NCT05677490)
DESCRIPTION:Nivolumab\, phase 3\, Gastric Cancer.\nStudy: mFOLFIRINOX Versu
 s mFOLFOX With or Without Nivolumab for the Treatment of Advanced\, Unrese
 ctable\, or Metastatic HER2 Negative Esophageal\, Gastroesophageal Junctio
 n\, and Gastric Adenocarcinoma\nEstimated primary completion: 8 November 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05677490
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03686124-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03686124)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: ACTengine® IMA203/IMA203CD8 as 
 Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractor
 y Solid Tumors\nEstimated primary completion: December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT03686124
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712875-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06712875)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: MAPK Inhibition Combined With An
 ti-PD1 Therapy for BRAF-altered Pediatric Gliomas\nEstimated primary compl
 etion: December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06712875
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06941857-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06941857)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: NC410 and FOLFIRINOX in Combinatio
 n With Nivolumab With or Without Ipilimumab in Patients With Untreated Met
 astatic Pancreatic Cancer\nEstimated primary completion: December 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06941857
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527858-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07527858)
DESCRIPTION:Nivolumab\, phase 2\, Colorectal Cancer.\nStudy: Study of Denik
 itug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adult
 s With Advanced Colorectal Cancer\nEstimated primary completion: December 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07527858
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07645118-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07645118)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Brachytherapy Followed by Nivoluma
 b Prior to Surgery in Rectal Cancer\nEstimated primary completion: Decembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0764511
 8
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06708949-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281215
DTEND;VALUE=DATE:20281216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06708949)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: A Randomize
 d Phase 2 Trial of Nivolumab\, Relatlimab Plus Ipilimumab vs. Nivolumab Pl
 us Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)\nEstimated
  primary completion: 15 December 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06708949
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03017820-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT03017820)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Vaccine (VSV-hIFNβ-NIS) With or
  Without Cyclophosphamide and Combinations of Ipilimumab\, Nivolumab\, and
  Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma\, Acute My
 eloid Leukemia or Lymphoma\nEstimated primary completion: 31 December 2028
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT03017820
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187429-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05187429)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Low Dose Nivolumab in Adults Liv
 ing With HIV on Antiretroviral Therapy\nEstimated primary completion: Janu
 ary 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05187
 429
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06697197-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290104
DTEND;VALUE=DATE:20290105
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06697197)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Study of BMS-986482 Alone or a
 s Combination Therapy in Participants With Advanced Solid Tumors\nEstimate
 d primary completion: 4 January 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06697197
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06622941-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06622941)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study to ONO-4538 in Patients With
  Rhabdoid Tumor\nEstimated primary completion: 31 January 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06622941
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06823479-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06823479)
DESCRIPTION:Nivolumab\, phase 2\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Towards Cure Via Only Ultra-short ICB in CSCC\nEstimated primary com
 pletion: February 2029. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06823479
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05629546-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Nivolumab: Phase 1 readout est. (NCT05629546)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Memory-Like Natural Kil
 ler Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma
  After Progression on Checkpoint Inhibitors\nEstimated primary completion:
  28 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ni
 volumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT05629546
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07740941-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07740941)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: NeoAdjuvant\, Spare-Adj
 uvant (NASA) in Stage IIIB-IV (M1a) Melanoma\nEstimated primary completion
 : March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7740941
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04248569-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290301
DTEND;VALUE=DATE:20290302
SUMMARY:Nivolumab: Phase 1 readout est. (NCT04248569)
DESCRIPTION:Nivolumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: DNAJB1-
 PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimuma
 b for Patients With Fibrolamellar Hepatocellular Carcinoma\nEstimated prim
 ary completion: 1 March 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT04248569
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06495125-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290317
DTEND;VALUE=DATE:20290318
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06495125)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Defac
 tinib\, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractor
 y LKB1-Mutant Advanced Non-Small Cell Lung Cancer\nEstimated primary compl
 etion: 17 March 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06495125
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07572123-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT07572123)
DESCRIPTION:Nivolumab\, phase 2/3.\nStudy: Evaluating the Addition of Maint
 enance Immunotherapy Compared to the Usual Treatment of Chemotherapy and A
 utologous Stem Cell Transplant Alone for High-risk Patients With Relapsed 
 or Refractory Hodgkin Lymphoma\nEstimated primary completion: 31 March 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07572123
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07532902-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07532902)
DESCRIPTION:Nivolumab\, phase 1\, Urothelial Carcinoma.\nStudy: A Study of 
 BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cance
 r\nEstimated primary completion: April 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07532902
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06188676-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290401
DTEND;VALUE=DATE:20290402
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06188676)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Nivolumab 40 mg in Combination Wit
 h Chemo-Immunotherapy for Newly Diagnosed Primary Mediastinal B-Cell Lymph
 oma\nEstimated primary completion: 1 April 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06188676
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06029270-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06029270)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Testing the Addition of BMS-986016
  (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recur
 rent or Metastatic Nasopharyngeal Cancer\nEstimated primary completion: 30
  April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivoluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 029270
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632327-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06632327)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Compa
 ring Impact of Treatment Before or After Surgery in Patients With Stage II
 -IIIB Resectable Non-small Cell Lung Cancer\nEstimated primary completion:
  30 April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06632327
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06812858-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06812858)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: PD-1 Inhibitors Maintenance for cH
 L Post-autoHCT\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06812858
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07504796-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07504796)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: ctDNA-guided Addition o
 f Ipilimumab to Patients Receiving Nivolumab and Relatlimab\nEstimated pri
 mary completion: May 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07504796
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06681298-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06681298)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A Multi-center\, Two-arm\, Phase 2
  Clinical Study on the Perioperative Treatment of HER2-positive Resectable
  Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FL
 OT and Trastuzumab VS FLOT Combined With Trastuzumab\nEstimated primary co
 mpletion: 1 May 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06681298
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459543-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290526
DTEND;VALUE=DATE:20290527
SUMMARY:Nivolumab: Phase 4 readout est. (NCT07459543)
DESCRIPTION:Nivolumab\, phase 4\, Melanoma.\nStudy: A Study to Assess the S
 afety\, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination 
 (FDC) In Unresectable or Metastatic Melanoma Participants In India\nEstima
 ted primary completion: 26 May 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07459543
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07501117-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07501117)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Neoadjuvant Immunothera
 py for Patients With High-risk Eye Melanoma\nEstimated primary completion:
  1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7501117
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06816927-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06816927)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Trial of Glioblastoma Immunotherap
 y Advancement With Nivolumab and Relatlimab\nEstimated primary completion:
  1 June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 6816927
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03258567-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290601
DTEND;VALUE=DATE:20290602
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03258567)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Nivolumab in Epstein-Barr Virus (E
 BV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLym
 phomas\nEstimated primary completion: 1 June 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03258567
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06240143-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06240143)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Intradermal Ipilimuma
 b and Nivolumab in High Risk Stage II Melanoma\nEstimated primary completi
 on: July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06240143
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07013565-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07013565)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Chemoimmunotherapy for ALK+ Relaps
 ed/Refractory ALCL\nEstimated primary completion: 1 July 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07013565
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06936943-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06936943)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: ONO-4538 Study in Patients With Ri
 chter's Transformation\nEstimated primary completion: 31 July 2029. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06936943
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05203172-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Nivolumab: Phase 4 readout est. (NCT05203172)
DESCRIPTION:Nivolumab\, phase 4.\nStudy: The FLOTILLA Study: Providing Cont
 inued Access to The Study Medicines Encorafenib and Binimetinib for Partic
 ipants in Prior Clinical Trials\nEstimated primary completion: 31 July 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05203172
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07694986-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07694986)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Trial of Therapies With IT cDC1s C
 ombined w/ IT Trastuzamab for Her+ or IT Nivolumab for Her- BC LMD\nEstima
 ted primary completion: August 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07694986
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431281-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290816
DTEND;VALUE=DATE:20290817
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07431281)
DESCRIPTION:Nivolumab\, phase 3\, Gastric Cancer.\nStudy: Sonesitatug Vedot
 in in Combination With Capecitabine With or Without Rilvegostomig in Parti
 cipants With Advanced or Metastatic Gastric\, Gastroesophageal Junction\, 
 or Esophageal Adenocarcinoma Expressing Claudin18.2\nEstimated primary com
 pletion: 16 August 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07431281
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03899155-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290825
DTEND;VALUE=DATE:20290826
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03899155)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Pan Tumor Rollover Study\nEstimate
 d primary completion: 25 August 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT03899155
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03228667-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03228667)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: QUILT
 -3.055: A Study of Combination Immunotherapies in Patients Who Have Previo
 usly Received Treatment With Immune Checkpoint Inhibitors\nEstimated prima
 ry completion: 31 August 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT03228667
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07576725-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07576725)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose\, Reduced Frequency Nivolumab for the Treatment of Unresectable or Met
 astatic Cancer\, AFFORD IO Trial\nEstimated primary completion: 31 August 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07576725
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07679841-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07679841)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Safety and Efficacy of Nivolumab
  and Imiquimod Combination in Vulvar Squamous Cell Carcinoma Patients\nEst
 imated primary completion: September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07679841
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563738-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07563738)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 2
 -part Phase 1/2 Open-label Trial on ODM-212\nEstimated primary completion:
  September 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivo
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07563738
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219459-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290930
DTEND;VALUE=DATE:20291001
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07219459)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Visugro
 mab\, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib i
 n Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Fa
 ilure\nEstimated primary completion: September 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07219459
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06871007-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06871007)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Nivolumab and DA-EPOCH-R in Pedi
 atric Primary Mediastinal (Thymic) Large B-cell Lymphoma\nEstimated primar
 y completion: 1 September 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06871007
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07818018-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290904
DTEND;VALUE=DATE:20290905
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07818018)
DESCRIPTION:Nivolumab\, phase 1/2\, Gastric Cancer.\nStudy: A Study of 2141
 -V11 in People With Esophageal\, Gastric\, or Gastroesophageal Junction Ad
 enocarcinoma\nEstimated primary completion: 4 September 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07818018
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07820813-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20290915
DTEND;VALUE=DATE:20290916
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07820813)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: bNAbs and Anti-PD-1 in HIV\nEstima
 ted primary completion: 15 September 2029. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07820813
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07234487-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07234487)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Comparison of AVD + Low-Dose Nivol
 umab vs. PET-Adapted BEACOPP-like in Advanced cHL\nEstimated primary compl
 etion: October 2029. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07234487
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07246863-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291001
DTEND;VALUE=DATE:20291002
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07246863)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Trial
  Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Tr
 eatment of Participants With Metastatic NSCLC\nEstimated primary completio
 n: 1 October 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ni
 volumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07246863
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07838974-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291101
DTEND;VALUE=DATE:20291102
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07838974)
DESCRIPTION:Nivolumab\, phase 1\, Melanoma.\nStudy: Adding Anakinra and Toc
 ilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patient
 s 50 Years of Age or Older\nEstimated primary completion: 1 November 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07838974
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665206-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291102
DTEND;VALUE=DATE:20291103
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04665206)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Stu
 dy to Evaluate VT3989 in Patients With Metastatic Solid Tumors\nEstimated 
 primary completion: 2 November 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT04665206
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902921-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07902921)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: STA
 R0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castr
 ate-Resistant Prostate Cancer\, and STAR0602 Alone in Thymic Carcinoma\nEs
 timated primary completion: 31 December 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07902921
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07546812-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07546812)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study of Denikitug (GS-1811) Given
  Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric
 \, Gastroesophageal Junction (GEJ)\, and Esophageal Adenocarcinomas\nEstim
 ated primary completion: January 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07546812
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581406-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT06581406)
DESCRIPTION:Nivolumab\, phase 2/3\, Melanoma.\nStudy: A Randomized\, Phase 
 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination Wit
 h Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Meta
 static Uveal Melanoma\nEstimated primary completion: January 2030. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06581406
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07718243-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07718243)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Inv
 estigating the Combination of Bexmarilimab and Nivolumab in Solid Tumours\
 , Melanoma and NSCLC\nEstimated primary completion: 31 January 2030. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07718243
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03811015-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Nivolumab: Phase 3 readout est. (NCT03811015)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Testing Immunotherapy Versus Obser
 vation in Patients With HPV Throat Cancer\nEstimated primary completion: 3
 1 January 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivol
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03811015
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432295-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07432295)
DESCRIPTION:Nivolumab\, phase 2\, Gastric Cancer.\nStudy: Givastomig Combin
 ed With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metast
 atic Gastric Cancer (GIVA-2)\nEstimated primary completion: March 2030. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07432295
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07210632-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300330
DTEND;VALUE=DATE:20300331
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07210632)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Window Trial of Fluorescently Labe
 led Nivolumab-IRDye800 (Nivo800) in High Grade Glioma (HGG)\nEstimated pri
 mary completion: 30 March 2030. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07210632
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926790-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06926790)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoad
 juvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)\nEstimated
  primary completion: 31 March 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06926790
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460765-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07460765)
DESCRIPTION:Nivolumab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head
  and Neck Squamous Cell Carcinoma (HNSCC)\nEstimated primary completion: A
 pril 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0746
 0765
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04564157-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Nivolumab: Phase 3 readout est. (NCT04564157)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: New A
 djuvant Trial of Chemotherapy vs Chemo-immunotherapy\nEstimated primary co
 mpletion: 1 April 2030. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT04564157
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07620574-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07620574)
DESCRIPTION:Nivolumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Long-Te
 rm Extension Study for Participants Previously Enrolled in an Exelixis-Spo
 nsored Study\nEstimated primary completion: 31 May 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07620574
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06889493-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300601
DTEND;VALUE=DATE:20300602
SUMMARY:Nivolumab: Phase 1 readout est. (NCT06889493)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: SVV-001 With Nivolumab and Ipilimu
 mab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC)
  or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)\nEstimated 
 primary completion: 1 June 2030. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06889493
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561386-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300730
DTEND;VALUE=DATE:20300731
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06561386)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Stu
 dy to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy v
 s Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-
 small Cell Lung Cancer With PD-L1 Expression ≥ 1%\nEstimated primary com
 pletion: 30 July 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06561386
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06683755-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300816
DTEND;VALUE=DATE:20300817
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06683755)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Phase I/IIa Dose Find
 ing Study of Triplet Regimen of Relatlimab Ipilimumab and NIvolumab in Fir
 st Line Therapy of Metastatic Melanoma (TRINITY)\nEstimated primary comple
 tion: 16 August 2030. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06683755
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06488482-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06488482)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: Assessment of Short Imm
 unotherapy After Radical Surgery of High-risk Malignant Melanoma\nEstimate
 d primary completion: September 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06488482
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987241-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300902
DTEND;VALUE=DATE:20300903
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT05987241)
DESCRIPTION:Nivolumab\, phase 2/3\, Urothelial Carcinoma.\nStudy: Testing t
 he Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use
  of Immunotherapy After Surgical Removal of the Bladder\, Kidney\, Ureter\
 , and Urethra for Urothelial Cancer Treatment\, MODERN Study\nEstimated pr
 imary completion: 2 September 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05987241
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872553-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300924
DTEND;VALUE=DATE:20300925
SUMMARY:Nivolumab: Phase 4 readout est. (NCT07872553)
DESCRIPTION:Nivolumab\, phase 4\, Renal Cell Carcinoma.\nStudy: A Study of 
 Treatment Delivery Preference In People With Kidney Cancer\nEstimated prim
 ary completion: 24 September 2030. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07872553
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06264180-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06264180)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: VO and Nivolumab vs Phy
 sician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-C
 TLA-4 Drugs [IGNYTE-3]\nEstimated primary completion: 30 September 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06264180
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07090148-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07090148)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Trial of pTVG-HP+Nivo+Targeted Abl
 ation of Resistant Lesions in Non-Castrate RecurrentOMPC\nEstimated primar
 y completion: October 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07090148
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430202-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07430202)
DESCRIPTION:Nivolumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: A DNAJB
 1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist 
 DRP-104\, Nivolumab\, and Ipilimumab in Patients With Advanced Stage Fibro
 lamellar Carcinoma (FLC)\nEstimated primary completion: October 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07430202
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07848295-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301018
DTEND;VALUE=DATE:20301019
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07848295)
DESCRIPTION:Nivolumab\, phase 1\, Renal Cell Carcinoma.\nStudy: A Study to 
 Assess the Safety and Tolerability of BMS-986527 in Participants With Clea
 r Cell Renal Cell Carcinoma (ccRCC)\nEstimated primary completion: 18 Octo
 ber 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07848
 295
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930182-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301021
DTEND;VALUE=DATE:20301022
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07930182)
DESCRIPTION:Nivolumab\, phase 2\, Melanoma.\nStudy: Adjuvant/Neoadjuvant Im
 munotherapy in Melanoma Based on Serial Plasma ctDNA Monitoring\nEstimated
  primary completion: 21 October 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07930182
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07223424-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301130
DTEND;VALUE=DATE:20301201
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07223424)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Patie
 nt Preference for Subcutaneous vs. Intravenous Immune Therapy\nEstimated p
 rimary completion: 30 November 2030. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07223424
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664176-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07664176)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: NgFUS NIVO: NeuroNavigation-Guided
  Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Oth
 er High Grade Brain Tumors\nEstimated primary completion: December 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07664176
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07031765-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07031765)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: Peds CHAMP1ON - Hematopoietic Stem
  Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-G
 rade Glioma\nEstimated primary completion: December 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07031765
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963905-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06963905)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Saci Nivo Rela for TNBC\nEstimat
 ed primary completion: December 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06963905
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07281924-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07281924)
DESCRIPTION:Nivolumab\, phase 1/2\, Melanoma.\nStudy: Hepzato Kit and Opdua
 lag for Metastatic Melanoma and Liver Metastasis\nEstimated primary comple
 tion: December 2030. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07281924
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07328087-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301202
DTEND;VALUE=DATE:20301203
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07328087)
DESCRIPTION:Nivolumab\, phase 1\, Colorectal Cancer.\nStudy: COLONYVAQ™\,
  a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage 
 III Colorectal Cancer\nEstimated primary completion: 2 December 2030. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07328087
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929041-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301212
DTEND;VALUE=DATE:20301213
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT04929041)
DESCRIPTION:Nivolumab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: Tes
 ting the Addition of Radiation Therapy to the Usual Treatment (Immunothera
 py With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Ca
 ncer Patients Who Are PD-L1 Negative\nEstimated primary completion: 12 Dec
 ember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 29041
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04159818-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301215
DTEND;VALUE=DATE:20301216
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04159818)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Immune Induction Strategies to Imp
 rove Response to Immune Checkpoint Blockade in Triple Negative Breast Canc
 er (TNBC) Patients\nEstimated primary completion: 15 December 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT04159818
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03138161-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT03138161)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: SAINT:Trabectedin\, Ipilimumab a
 nd Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma\nEstimate
 d primary completion: 31 December 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03138161
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03886311-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03886311)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Talimogene Laherparepvec\, Nivolum
 ab and Trabectedin for Sarcoma\nEstimated primary completion: 31 December 
 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT03886311
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06715241-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06715241)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A MULTICENTER\, SEEKING SIGNAL\, R
 ANDOMISED\, OPEN-LABEL PHASE II OF RELATLIMAB AND NIVOLUMAB VS NIVOLUMAB A
 LONE IN LOCALLY ADVANCED CERVICAL CANCERS\nEstimated primary completion: 3
 1 December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivo
 lumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06715241
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07551583-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07551583)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Phase II Study Of Nivolumab Plus A
 VD In Pediatric\, Adolescent\, And Young Adult Patients With CHL\nEstimate
 d primary completion: 31 December 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07551583
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07050043-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07050043)
DESCRIPTION:Nivolumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Low D
 ose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Tre
 atment in Advanced or Metastatic NSCLC\nEstimated primary completion: 31 D
 ecember 2030. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7050043
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03815890-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03815890)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Pre-operative Trial for Breast Can
 cer With Nivolumab in Combination With Novel IO\nEstimated primary complet
 ion: 1 January 2031. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03815890
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02813135-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310228
DTEND;VALUE=DATE:20310301
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT02813135)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: European Proof-of-Concept Therap
 eutic Stratification Trial of Molecular Anomalies in Relapsed or Refractor
 y Tumors\nEstimated primary completion: February 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02813135
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06618287-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310226
DTEND;VALUE=DATE:20310227
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06618287)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: A Study to Evaluate the Safety\,
  Tolerability\, Drug Levels\, and Preliminary Efficacy of BMS-986507 Combi
 nations in Adult Participants With Advanced Solid Tumors\nEstimated primar
 y completion: 26 February 2031. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06618287
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04910347-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04910347)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Consolidation Nivolumab After Conc
 urrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma\nEst
 imated primary completion: April 2031. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT04910347
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05675410-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310428
DTEND;VALUE=DATE:20310429
SUMMARY:Nivolumab: Phase 3 readout est. (NCT05675410)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: A Study to Compare Standard Therap
 y to Treat Hodgkin Lymphoma to the Use of Two Drugs\, Brentuximab Vedotin 
 and Nivolumab\nEstimated primary completion: 28 April 2031. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05675410
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06866262-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310801
DTEND;VALUE=DATE:20310802
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT06866262)
DESCRIPTION:Nivolumab\, phase 1/2\, Renal Cell Carcinoma.\nStudy: Inulin Ge
 l in Combination With Ipilimumab and Nivolumab for the Treatment of Metast
 atic or Locally Advanced Kidney Cell Cancer\, ICON Trial\nEstimated primar
 y completion: 1 August 2031. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06866262
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05934331-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310806
DTEND;VALUE=DATE:20310807
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05934331)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: A LM-302 Combination With Other An
 ti-Tumor Therapies Phase ll Study\nEstimated primary completion: 6 August 
 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05934331
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895709-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT04895709)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A S
 tudy of BMS-986340 as Monotherapy and as Combination Therapy in Participan
 ts With Advanced Solid Tumors\nEstimated primary completion: 31 August 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT04895709
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04929028-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310915
DTEND;VALUE=DATE:20310916
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04929028)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Therapy Adapted for High Risk and 
 Low Risk HIV-Associated Anal Cancer\nEstimated primary completion: 15 Sept
 ember 2031. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT049
 29028
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741565-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20310930
DTEND;VALUE=DATE:20311001
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07741565)
DESCRIPTION:Nivolumab\, phase 1\, Head and Neck Squamous Cell Carcinoma.\nS
 tudy: Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled
  Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)\nEst
 imated primary completion: 30 September 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07741565
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07689175-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07689175)
DESCRIPTION:Nivolumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Adaptiv
 e Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma\nEst
 imated primary completion: 31 October 2031. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07689175
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07338981-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07338981)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: The Impact of Time-of-day-Dependen
 t Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall 
 Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter\, 
 Randomized Controlled Trial.\nEstimated primary completion: December 2031.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07338981
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07444619-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Nivolumab: Phase 1 readout est. (NCT07444619)
DESCRIPTION:Nivolumab\, phase 1.\nStudy: A Phase I Study of Pazopanib in Co
 mbination With Trabectedin\, Ipilimumab and Nivolumab (TraPIN) in Pediatri
 c and Young Adult Patients With Recurrent Soft Tissue Sarcomas\nEstimated 
 primary completion: 31 December 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07444619
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06745076-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320103
DTEND;VALUE=DATE:20320104
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06745076)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Personalized Reduction of Chemothe
 rapy Intensity Through ctDNA Evaluation for the Treatment of Patients With
  Advanced Hodgkin Lymphoma\nEstimated primary completion: 3 January 2032. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06745076
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05533697-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320218
DTEND;VALUE=DATE:20320219
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT05533697)
DESCRIPTION:Nivolumab\, phase 1/2.\nStudy: Study of mRNA-4359 Administered 
 Alone and in Combination With Immune Checkpoint Blockade in Participants W
 ith Advanced Solid Tumors\nEstimated primary completion: 18 February 2032.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT05533697
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03026140-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320301
DTEND;VALUE=DATE:20320302
SUMMARY:Nivolumab: Phase 2 readout est. (NCT03026140)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Neoadjuvant Immune Checkpoint Inhi
 bition and Novel IO Combinations in Early-stage Colon Cancer\nEstimated pr
 imary completion: 1 March 2032. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT03026140
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06794775-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320415
DTEND;VALUE=DATE:20320416
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06794775)
DESCRIPTION:Nivolumab\, phase 3\, Melanoma.\nStudy: SWE-NEO: Swedish NeoAdj
 uvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable 
 Stage III Melanoma\nEstimated primary completion: 15 April 2032. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06794775
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Nivolumab: Phase 2 readout est. (NCT04114136)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Anti-
 PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies\nEstimated p
 rimary completion: 30 April 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04114136
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06773910-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Nivolumab: Phase 2 readout est. (NCT06773910)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: BMS-986489 (Atigotatug + Nivolumab
 ) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)\nEstima
 ted primary completion: May 2032. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06773910
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06364631-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320505
DTEND;VALUE=DATE:20320506
SUMMARY:Nivolumab: Phase 3 readout est. (NCT06364631)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: CARE1 Pragmatic Clinical Trial\nEs
 timated primary completion: 5 May 2032. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06364631
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05112601-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320730
DTEND;VALUE=DATE:20320731
SUMMARY:Nivolumab: Phase 2 readout est. (NCT05112601)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Testing Nivolumab With or Without 
 Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometria
 l Carcinoma\nEstimated primary completion: 30 July 2032. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05112601
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07355205-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20320731
DTEND;VALUE=DATE:20320801
SUMMARY:Nivolumab: Phase 1/2 readout est. (NCT07355205)
DESCRIPTION:Nivolumab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Fir
 st-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803)
  in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer\nEstima
 ted primary completion: 31 July 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07355205
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07644312-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20330301
DTEND;VALUE=DATE:20330302
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07644312)
DESCRIPTION:Nivolumab\, phase 2.\nStudy: Study of Relatlimab and Nivolumab 
 (Opdualag) in Replication Repair Deficient HGG and DIPG\nEstimated primary
  completion: 1 March 2033. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07644312
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02339571-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20330630
DTEND;VALUE=DATE:20330701
SUMMARY:Nivolumab: Phase 2/3 readout est. (NCT02339571)
DESCRIPTION:Nivolumab\, phase 2/3\, Melanoma.\nStudy: A Phase II/III Trial 
 of Nivolumab\, Ipilimumab\, and GM-CSF in Patients With Advanced Melanoma\
 nEstimated primary completion: 30 June 2033. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/nivolumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT02339571
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07510334-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20330801
DTEND;VALUE=DATE:20330802
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07510334)
DESCRIPTION:Nivolumab\, phase 2\, Renal Cell Carcinoma.\nStudy: VSV-IFNβ-N
 IS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastat
 ic Clear Cell Renal Cell Carcinoma\nEstimated primary completion: 1 August
  2033. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/nivolumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07510334
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07405164-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20340422
DTEND;VALUE=DATE:20340423
SUMMARY:Nivolumab: Phase 3 readout est. (NCT07405164)
DESCRIPTION:Nivolumab\, phase 3.\nStudy: Extension Study for Participants i
 n Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)\nEstimated p
 rimary completion: 22 April 2034. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/nivolumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07405164
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770100-1974@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20400228
DTEND;VALUE=DATE:20400229
SUMMARY:Nivolumab: Phase 2 readout est. (NCT07770100)
DESCRIPTION:Nivolumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Concu
 rrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation 
 Therapy (SBRT) for Stage IV Cancers (COINSSS IV)\nEstimated primary comple
 tion: 28 February 2040. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/nivolumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07770100
URL:https://assetmemo.bio/drug/nivolumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
